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We tested whether loss of eukaryotic elongation factor 2 kinase
(eEF2K) activity in macrophages suppresses development of athero-
sclerosis by transplanting bone marrow from mice with mutant eEF2K
into ldlr/ mice. Sixteen weeks after high-fat diet feeding, mutant
eEF2K hematopoietic chimeras had a dramatically reduced level of
atherosclerotic plaque formation. M1-skewed macrophages from
eEF2K knock-in mice have less tumour necrosis factor-a release and a
lesser ability to induce expression of endothelial cell markers,
providing a potential explanation for the role of eEF2K. Because eEF2K
activity in cells of the hematopoietic compartment contributes to
atherosclerosis development, drugs inhibiting eEF2K might have a
beneﬁcial effect in treatment of atherosclerosis.Received for publication September 11, 2014. Accepted September 23, 2014.
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Nous avons veriﬁe si la perte d’activite kinase du facteur d’elongation-2
eucaryote (eEF2K) dans les macrophages inhibe le developpement de
l’atherosclerose en transplantant la moelle osseuse des souris eEF2K
mutantes aux souris ldlr/. Seize (16) semaines après avoir commence
un regime riche en matières grasses, les chimères hematopoïetiques
eEF2Kmutantes ont presente une reduction notable de la formation de la
plaque d’atherosclerose. Les macrophages de type M1 des souris knoc-
kin eEF2K presentent une moins grande liberation du facteur de
necrose tumorale a et une moindre capacite à induire l’expression des
marqueurs des cellules endotheliales, ce qui explique potentiellement le
rôle de la eEF2K. Puisque l’activite de la eEF2K des compartiments cel-
lulaires de l’hematopoïèse contribue au developpement de l’ath-
erosclerose, les medicaments inhibant la eEF2K auraient un effet
beneﬁque dans le traitement de l’atherosclerose.Eukaryotic elongation factor 2 kinase (eEF2K) regulates protein
synthesis via phosphorylation of its only known substrate,
eukaryotic elongation factor 2 (eEF2)1,2; impaired binding of
eEF2 to the ribosome and its dissociation from the ribosomal
complex suppresses translocation of peptidyl-transfer RNAs.3,4
Numerous signalling pathways regulate phosphorylation of
eEF2K at multiple activating or inhibitory sites, indicating its
central role in regulating protein synthesis.5-7 eEF2K expression
is upregulated in many cancers, and eEF2K promotes tumour
survival by inhibiting protein synthesis during nutrient depri-
vation.8 eEF2K is also involved in neuronal development and
synaptic plasticity.9,10 Deﬁciency of eEF2K activity induces
fast-acting behavioural antidepressant effects, suggesting a po-
tential use of eEF2K inhibitors as antidepressants.11 Morerecently, our laboratory and another have suggested that eEF2K
is important in cardiovascular diseases.12,13
Atherosclerosis is recognized as a chronic inﬂammatory disease
with a complex aetiology.14,15 Endothelial dysfunction, lipid
retention, and an oxidative microenvironment are all thought to
contribute tomacrophage activation, survival, and/or proliferation
and the subsequent development of early atherosclerotic lesions.16
A key mediator in the pathogenesis of this disease, oxidized low-
density lipoprotein (oxLDL) has been shown to block apoptosis
of macrophages through various signalling pathways.17
We showed that the eEF2K signalling pathway was activated
by oxLDL.12 Impairment of eEF2K activity suppressed the
prosurvival effect of oxLDL, suggesting eEF2K could inﬂuence
the effect of macrophages on atherosclerosis. Using a targeted
knock-in mouse strain with a mutation in the kinase-domain of
eEF2K (eef2k-KI18), we investigated whether eEF2K deﬁciency
affects atherosclerosis development in vivo in low-density lipo-
protein receptor-deﬁcient (ldlr/) mice. Wild type (WT) or
eef2k-KI bone marrow was transplanted into irradiated ldlr/
mice. These hematopoietic chimeras were then fed a high-fat diet
(HFD) for 16 weeks, allowing them to develop atherosclerosis.
The extent of atherosclerosis was subsequently analyzed by enll rights reserved.
Figure 1. En face staining of plaque area after 16 weeks of high fat diet feeding. Chimeric ldlr/ mice were generated via lethal irradiation and
transplantation with bone marrow from BL/6 (wild type [WT]) or eef2k-KI (knock-in [KI]) mice. Chimeric hearts were harvested after 16 weeks of high-
fat diet feeding. (A) Representative images of Sudan IV-stained aorta show the difference in plaque area between WT and KI chimeric groups. (B)
Quantiﬁcation of relative plaque area (plaque area divided by total aorta area), which was performed by a blinded observer, shows that reduced
activity of eukaryotic elongation factor 2 kinase in the hematopoietic compartment reduces plaque area from 13.0% (WT) to 7.7% (KI). WT: n ¼ 12;
KI: n ¼ 10; P ¼ 0.036, Student t test.
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Red-O staining of aortic root cross-sections. Our ﬁndings
revealed a signiﬁcant reduction in atherosclerosis in mice who
received a transplant of bonemarrow reconstituted from eef2k-KI
mice, and thus revealed eEF2K as a potential target for therapy.
We also report ﬁndings suggesting that tumour necrosis factor
(TNF)-a release by M1-skewed macrophage cells is impaired
when eEF2K activity is suppressed, thus providing a possible
mechanistic explanation of the effects we have observed in vivo.
Methods
Mice
Generation of eef2k-KI transgenic knock-in (KI) mice have
been described previously.18 These mice were crossed with WT
C57BL/6 mice (strain code: 027, Charles River, Sherbrooke,
Canada) for 6 generations to express kinase-inactive eEF2K in the
C57BL/6 background. ldlr/ C57BL6 mice (strain name:
B6.129S7-Ldlrtm1Her/J, stock number: 002207) were purchased
from Jackson Laboratory. Mice were obtained and handled ac-
cording to University of British Columbia ethics protocols A11-
0141 and A10-0087.
Bone marrow transplantation
The ldlr/ recipients were lethally irradiated using 14 mi-
nutes of exposure to 850-rad gamma irradiation (two 7-minute
sessions). Donor bone marrow cells (2  106) from eithereef2k-KI or WT mice in 200 mL Hanks balanced salt solution
were injected into the tail veins of the irradiated recipients.
Chimeric animals recovered for 4 weeks before feeding the
HFD. Animals were routinely monitored, and no major dif-
ferences in weight or behaviour were noted between the groups.
Atherosclerotic lesion analysis
Chimeric mice fed the HFD for 8 or 16 weeks were anaes-
thetized using intraperitoneal injection of 200 mL/10 g body
weight of 2.5% avertin in phosphate-buffered saline (PBS), then
perfused with 10 mL of 4% paraformaldehyde, 7.5% sucrose,
and 0.5 mM ethylenediaminetetraacetic in PBS and ﬂushed
with 10 mL of 0.5 mM ethylenediaminetetraacetic in PBS.
Hearts and aortas were harvested and stored in 10% formalde-
hyde. Lesion quantiﬁcation was performed as described.19 For
en face staining, aortas were opened longitudinally and pinned
on a black wax pan for Sudan IV staining. For aortic root lesion
quantiﬁcation, the upper portions of the hearts were sent to
Wax-It Histology Service Inc (Vancouver, British Columbia,
Canada) for sectioning and hematoxylin and eosin andOil-Red-
O staining. The ratios of lipid-rich area to the total aortic area
(en face staining) or the total lesion area (aortic sections) were
calculated.
Macrophage conditioned media preparation and assays
Bone marrow-derived macrophages were isolated from fe-
murs of 6- to 8-week-old eEF2K-KI or WT mice as
Figure 2. Plaque area in the aortic root after 16 weeks of high-fat diet. Chimeric animal hearts were harvested after 16 weeks of high-fat diet and
compared with wild type (WT). Representative images of hematoxylin and eosin stained (A) and Oil-Red-O stained (B) aortic root show the difference
of plaque area between WT and eef2k-KI (KI) groups. (C) Quantiﬁcation of relative plaque area (plaque area over total aortic sectional area) in the
aortic root, which was performed by a blinded observer, shows that reduced activity of eukaryotic elongation factor 2 kinase in the hematopoietic
cells reduces plaque area from 45.2% (WT) to 37.7% (KI). WT: n ¼ 6; KI: n ¼ 6; P ¼ 0.033, Student t test.
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days. Conditioned medium (CM) was harvested after 24-hour
treatment with polarization factors: 10 ng/mL lipopolysac-
charide plus 10 U/mL interferon-g (for M1) or 10 ng/mL
interleukin-4 (for M2), or from macrophages left in normal
medium (M0 cells).
For endothelial cell response, early passages of human
umbilical vein endothelial cells (HUVEC) were cultured in
endothelial basal medium supplemented with EGM-2 Bul-
letKit (Lonza, Mississauga, Canada). CM was applied to
HUVEC cells at 80% conﬂuency. After 5 hours, HUVEC
cells were harvested for RNA extraction and subsequent
quantitative polymerase chain reaction analysis for levels of
vascular cell adhesion molecule-1 (VCAM-1) intercellular
adhesion molecule-1 (ICAM-1), E-selectin, and P-selectin.
An enzyme-linked immunosorbent assay kit from BD Bio-
sciences (Mississauga, Ontario, Canada) was used to test the
CM for TNF-a. CM samples were diluted 100 times to ensure
concentrations were within range of the standard curve.Results
Hearts and aortas were harvested from chimeric mice, with
bone marrow from either eef2k-KI mice or from WT BL/6
mice, after feeding a HFD for 8 or 16 weeks. En face staining
of aortas in situ with Sudan IV was used to measure the lipid-
containing surface area as a measure of the extent of athero-
sclerotic plaques. In mice who received a transplant of bonemarrow from eef2k-KI mice, a striking reduction in lipid
staining was observed after 16 weeks of receiving the HFD.
Plaque areas were reduced from 13.0% (WT) to 7.7% (KI), a
reduction of just > 40% (Fig. 1). Oil-Red-O staining was
used to determine the extent of lipid deposits in aortic root
cross-sections from harvested hearts. There was a signiﬁcant
decrease in plaque area in mice who received a transplant of
bone marrow from eef2k-KI mice, 37.7%, compared with
45.2% in mice with WT bone marrow, also a statistically
signiﬁcant reduction (Fig. 2).
Although we saw a small decrease in atherosclerosis in the
KI group after 8 weeks, it was not statistically signiﬁcant (not
shown), which might be attributed to the low degree of
atherosclerosis observed at this very early time point. The
possibility that the 2 groups of mice might have had different
lipid proﬁles was ruled out (Supplemental Fig. 1). We also
veriﬁed that macrophages isolated from the eef2k-KI mice had
no detectable increase in eEF2 phosphorylation when stimu-
lated with oxLDL (Supplemental Fig. 2).
As a source of cytokines, macrophages have paracrine ef-
fects on neighbouring cells, such as endothelial cells, and thus
we tested if such activity might be altered by a deﬁciency in
eEF2K activity. CM from macrophage cultures were tested for
their effects on surface marker expression on endothelial cells.
To mimic potential effects of inﬂammatory vs healer (M1 vs
M2) macrophages, we compared macrophage CM from M0,
M1, and M2 cells, each isolated from WT or eef2k-KI mice.
CM from inﬂammatory M1 cells showed much greater
Figure 3. Lack of eukaryotic elongation factor 2 kinase activity compromises M1 cytokine-induced adhesion molecule expression in HUVECs. Mac-
rophages were cultured in macrophage colony stimulating factorecontaining media for 11 days. Cells were counted and seeded at the same con-
centration. Ten ng/mL lipopolysaccharide and 10 U/mL interferon-g or 10 ng/mL interleukin-4 were added to polarize macrophages toward either the
M1 or M2 subtype, respectively. Conditioned media (CM) was collected after 24 hours. VCAM-1 (A), ICAM-1 (B), E-selectin (SELE; C), and P-selectin
(SELP;D) gene expressionwere determined in HUVEC cells incubatedwith the CM. CM from cells with inactivated eukaryotic elongation factor 2 kinase
(KI groups) resulted in a reduced level of induction by the M1-conditioned media for VCAM-1, ICAM-1, and SELE, but not SELP. No signiﬁcant changes
were observed in the effects of CM fromM0orM2cells. (E) After 24hours, preparedCMwascollected. Concentrationsof tumour necrosis factor (TNF)-a
were detected using enzyme-linked immunosorbent assay. Only M1 cultures produced signiﬁcant levels of TNF-a, and M1 cells from eef2k-KI mice
produced less TNF-a compared with the wild type (WT) cells. Results shown are from a single experiment using triplicate samples but the same trend
was observed in 3 separate experiments for the HUVEC markers, but only a single experiment could be done for TNF-a analysis. HUVEC, human
umbilical vein endothelial cells; ICAM-1, intercellular adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1.
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VCAM-1 and ICAM-1. CM from similarly induced cells
lacking eEF2K activity showed a marked reduction in activity
(Fig. 3A-C). Levels of P-selectin expression were not affected
by loss of eEF2K (Fig. 3D).
TNF-a is the key factor secreted by macrophages that
regulate endothelial cell adhesion molecule expression. TNF-a
concentrations in macrophage CM was highest in M1 condi-
tioned media, as expected, and barely detected in M2 or M0
CM. Comparison of CM from WT or eef2k-KI cells showed
that the TNF-a produced in the absence of eEF2K activity was
reduced, matching the pattern of CM-induced adhesion
molecule expression levels in endothelial cells (Fig. 3E).Discussion
Atherosclerotic plaques develop over an extended time
period, with the initial processes at the endothelial lining
causing activation of macrophages and their recruitment into
the vessel walls, taking years (in humans) to cause any evi-
dence of plaque formation. Macrophages are key players in
that they respond to signals at the endothelial lining, and
differentiate into foam cells as a result of accumulation of
cholesterol and its byproducts from uptake of altered forms of
low-density lipoprotein. We showed previously that survival
of macrophages in the presence of oxLDL involves eEF2K, a
regulator of protein translation.12 Based on the premise that
macrophage survival contributes to their persistence in the
intima, we postulated that blocking eEF2K activity mightsuppress development of atherosclerosis. We have tested this
hypothesis in the ldlr/ mouse model by generating he-
matopoietic chimeras using bone marrow cells from mice
expressing kinase-defective eEF2K (eef2k-KI) to engraft
lethally irradiated ldlr/ recipients. After recovery, these
chimeras were fed a high-fat diet to induce atherosclerosis and
mice with mutant eEF2K had a greatly reduced level of
atherosclerosis.
The ability of eEF2K to suppress protein synthesis, via
phosphorylation of eEF2, is well characterized and is impor-
tant in cellular responses to stress. Nutrient deprivation
leading to activation of adenosine monophosphate-activated
kinase, can contribute to eEF2K activation and the reduced
protein synthesis serves as an important energy-saving mech-
anism.8 Before our study, no link had been reported between
eEF2K activity and macrophage survival, and the current
study emphasizes the potential importance of this pathway in
the development of atherosclerosis. We have not yet been able
to determine whether a difference in macrophage apoptosis
can be detected in vivo, but this might be technically difﬁcult,
because a difference in apoptotic cells might only occur at
early time points in disease progression, and it is well known
that apoptotic cells are rapidly cleared in vivo. More studies
will be required to investigate this question.
We have also shown that when eEF2K activity is impaired,
the secretory proﬁle of macrophages is changed, which might
affect macrophage function in regulating the microenviron-
ment and neighbouring cells (Fig. 3). We have assessed this
function by measuring the expression of adhesion molecules,
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HUVEC cells incubated with macrophage CM. Elevated
levels VCAM-1, ICAM-1, and E-selectin were induced by
TNF-a produced by M1 macrophages, and these proteins are
known to result in enhanced progression of atheroscle-
rosis.20,21 It should be noted that the lack of change in P-
selectin message level might not be surprising because its
regulation occurs mostly at the level of surface expression of
preformed protein.22 M1 cells derived from eef2k-KI mice had
considerably less activity in their CM, corresponding with a
decrease in TNF-a.
Further characterization of macrophages lacking eEF2K
activity, and analysis of changes in numbers or characteristics
of macrophages that are present in plaques are the next steps
in this project. We will also want to determine if suppression
of endothelial cell surface proteins can be observed in the
absence of eEF2K in vivo. Finally, it will be important to
begin testing eEF2K inhibitors in vivo for their effectiveness
in blocking atherosclerosis development. Although our studies
show a partial block of atherosclerosis when eEF2K activity is
suppressed, eEF2K inhibitors might become even more
valuable when used together with other atherosclerosis drug
therapies. Recent studies have implicated eEF2K activity in
other conditions that also highlight its potential as an
important drug target, including in cancer.8 In the future, it
will be important to test newer speciﬁc eEF2K inhibitors in
multiple animal models, to evaluate their potential as therapies
for multiple disease targets.Acknowledgements
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